BLAINJECTIONINJECTABLE
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TRAZIMERA (trastuzumab-qyyp) by Pfizer is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2019.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAZIMERA (trastuzumab-qyyp) is a monoclonal antibody biosimilar to Herceptin that targets HER2/neu receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. It is indicated for HER2-positive breast cancer and gastric cancer patients. This is a reference-priced biologic in a crowded competitive segment.
$0.005BPart D
PeakProduct is at peak commercial maturity with modest Medicare spending; team focus is on maintaining market access and share against multiple biosimilar competitors.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRAZIMERA has zero linked job postings in current dataset, reflecting either minimal brand team size or decentralized commercial organization. Career opportunities align with biosimilar mature-stage roles: payer relations, market access, health economics, and competitive intelligence.
Company
Worked on TRAZIMERA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.